Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 30, pp. 3401-3408
Closed Access | Times Cited: 360

Showing 1-25 of 360 citing articles:

Cholangiocarcinoma — evolving concepts and therapeutic strategies
Sumera I. Ilyas, Shahid A. Khan, Christopher L. Hallemeier, et al.
Nature Reviews Clinical Oncology (2017) Vol. 15, Iss. 2, pp. 95-111
Open Access | Times Cited: 1357
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot, Andrea Necchi, Se Hoon Park, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 4, pp. 338-348
Open Access | Times Cited: 1137
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 686
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve A. Lowery, Rachna T. Shroff, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 3, pp. 276-282
Open Access | Times Cited: 616
FGF/FGFR signaling in health and disease
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 600
Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 491
Implementing Genome-Driven Oncology
David M. Hyman, Barry S. Taylor, José Baselga
Cell (2017) Vol. 168, Iss. 4, pp. 584-599
Open Access | Times Cited: 467
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 2, pp. 157-165
Open Access | Times Cited: 392
Glioblastoma targeted therapy: updated approaches from recent biological insights
Mehdi Touat, Ahmed Idbaïh, Marc Sanson, et al.
Annals of Oncology (2017) Vol. 28, Iss. 7, pp. 1457-1472
Open Access | Times Cited: 386
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 1, pp. 3-15
Open Access | Times Cited: 343
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano, Yao Lu, Alberto Servetto, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 334
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 328
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 170-185
Open Access | Times Cited: 300
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy Perera, Eleonora Jovcheva, Laurence Mévellec, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 6, pp. 1010-1020
Open Access | Times Cited: 282
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram, Matthew T. Chang, Philip Jonsson, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 12, pp. 735-748
Open Access | Times Cited: 276
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, et al.
Oncotarget (2016) Vol. 8, Iss. 9, pp. 16052-16074
Open Access | Times Cited: 269
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, et al.
European Urology (2018) Vol. 75, Iss. 3, pp. 423-432
Closed Access | Times Cited: 256
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano, Alessandra Fucci, Veroniquè Frattini, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 14, pp. 3307-3317
Open Access | Times Cited: 245
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Andō, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3491-3491
Open Access | Times Cited: 245
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda, Antoîne Italiano, Cinta Hierro, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 16, pp. 4888-4897
Open Access | Times Cited: 222
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
Trends in Pharmacological Sciences (2016) Vol. 37, Iss. 12, pp. 1081-1096
Closed Access | Times Cited: 187
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Martin Schüler, Byoung Chul Cho, Cyrus Sayehli, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 10, pp. 1454-1466
Closed Access | Times Cited: 153
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu, et al.
PLoS ONE (2020) Vol. 15, Iss. 4, pp. e0231877-e0231877
Open Access | Times Cited: 141
Page 1 - Next Page

Scroll to top